A Phase 1 Study of the Safety and Immunogenicity of DNA/MVA Immunizations With Co-Expressed GM-CSF in HIV-1 Infected Young Adults With Suppressed Viremia on HAART.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2013
At a glance
- Drugs HIV DNA vaccine (Primary) ; MVA-HIV62 (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Aug 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Jul 2013 Status changed from planning to not yet recruiting, as reported by ClinicalTrials.gov.